Concepedia

Gil Bar‐Sela

GB

Statistics

Publications

108

Citations

5.8K

H-Index

40

Active since

2001

Affiliations

Technion – Israel Institute of Technology(Current)

Rambam Health Care Campus

Emek Medical Center

Sheba Medical Center

University of Haifa

Gil Bar‐Sela is an author at Technion – Israel Institute of Technology specializing in oncology, medicine, and supportive care in cancer.

Publications per year

2001–2025

108

Publications

108

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial

Alexander Eggermont, Christian U. Blank, Mario Mandalà et al. · The Lancet Oncology · 2021 · 389 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma

Paolo A. Ascierto, Pier Francesco Ferrucci, Rosalie Fisher et al. · Nature Medicine · 2019 · 323 citations

Pharmacy, Oncology, Pharmacotherapy +12

Curcumin and Gemcitabine in Patients With Advanced Pancreatic Cancer

Ron Epelbaum, Moshe Schaffer, B. Vizel et al. · Nutrition and Cancer · 2010 · 279 citations

Medicine, Oncology, Pharmacology +13

Art therapy improved depression and influenced fatigue levels in cancer patients on chemotherapy

Gil Bar‐Sela, Lily Atid, Sara Danos et al. · Psycho-Oncology · 2007 · 233 citations

Medicine, Oncology, Cancer Symptom Management +16

Gut microbiota dependent anti-tumor immunity restricts melanoma growth in Rnf5−/− mice

Yan Li, Roberto Tinoco, Lisa Elmeń et al. · Nature Communications · 2019 · 228 citations · Full text

Life Sciences, Immunology, Oncology +17

1–5 of 108